Sanofi’s MS Candidate Tolebrutinib On Clinical Hold Following Liver Toxicities
But Studies Going Strong
Executive Summary
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
You may also be interested in...
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Biopharma’s Must-Know Q4 Catalysts
Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too.
Novartis’s Remibrutinib Succeeds In Pivotal CSU Trials With Promise Of Liver Safety
The major’s BTK inhibitor candidate, remibrutinib, met the primary and secondary endpoints of two Phase III trials in chronic spontaneous urticaria, with unproblematic liver function results so far, suggesting it may avoid pitfalls faced by rivals.